These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31686392)

  • 1. Genetic Alterations in Patients with Two Clinical Phenotypes of Multiple Sclerosis.
    Feliciano LM; Sávio ALV; de Castro Marcondes JP; da Silva GN; Salvadori DMF
    J Mol Neurosci; 2020 Jan; 70(1):120-130. PubMed ID: 31686392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
    Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
    J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
    Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
    Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
    Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
    Shimizu F; Tasaki A; Sano Y; Ju M; Nishihara H; Oishi M; Koga M; Kawai M; Kanda T
    PLoS One; 2014; 9(3):e92872. PubMed ID: 24686948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases.
    Nali LH; Olival GS; Sousa FTG; de Oliveira ACS; Montenegro H; da Silva IT; Dias-Neto E; Naya H; Spangenberg L; Penalva-de-Oliveira AC; Romano CM
    Mult Scler Relat Disord; 2020 Sep; 44():102243. PubMed ID: 32559700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
    Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
    Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
    Gandhi R; Healy B; Gholipour T; Egorova S; Musallam A; Hussain MS; Nejad P; Patel B; Hei H; Khoury S; Quintana F; Kivisakk P; Chitnis T; Weiner HL
    Ann Neurol; 2013 Jun; 73(6):729-40. PubMed ID: 23494648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
    Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
    Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of endogenous antiradical protective system in multiple sclerosis.
    Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
    Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis.
    Filion LG; Matusevicius D; Graziani-Bowering GM; Kumar A; Freedman MS
    Clin Immunol; 2003 Feb; 106(2):127-38. PubMed ID: 12672403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortical dysfunction underlies disability in multiple sclerosis.
    Vucic S; Burke T; Lenton K; Ramanathan S; Gomes L; Yannikas C; Kiernan MC
    Mult Scler; 2012 Apr; 18(4):425-32. PubMed ID: 21965421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS.
    Sørensen TL; Sellebjerg F
    Neurology; 2001 Oct; 57(8):1371-6. PubMed ID: 11673573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
    Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
    J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
    [No Abstract]   [Full Text] [Related]  

  • 15. Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis.
    Takewaki D; Suda W; Sato W; Takayasu L; Kumar N; Kimura K; Kaga N; Mizuno T; Miyake S; Hattori M; Yamamura T
    Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22402-22412. PubMed ID: 32839304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Silico Analysis Highlights Potential Predictive Indicators Associated with Secondary Progressive Multiple Sclerosis.
    Calabrò M; Lui M; Mazzon E; D'Angiolini S
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.
    Mancuso R; Hernis A; Agostini S; Rovaris M; Caputo D; Clerici M
    J Transl Med; 2015 May; 13():148. PubMed ID: 25947625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis.
    Iacobaeus E; Douagi I; Jitschin R; Marcusson-Ståhl M; Andrén AT; Gavin C; Lefsihane K; Davies LC; Mougiakakos D; Kadri N; Le Blanc K
    Immunol Cell Biol; 2018 Sep; 96(8):820-830. PubMed ID: 29569304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between TNFA, IL10 and IL18 promoter gene variants and cognitive functions in patients with relapsing-remitting multiple sclerosis.
    Trenova AG; Miteva LD; Stanilova SA
    J Neuroimmunol; 2020 Oct; 347():577357. PubMed ID: 32795736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
    Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.